Vogloyd 3D 2.2 Tablet SR
By Vogloyd 3D
Rx
15 Tablet SR in a Strip

Composition
Glimepiride(2mg) + Metformin(500mg) + Voglibose(0.2mg)

Manufacturer - Lloyd Healthcare Pvt Ltd
702, Balaji Business Park, Andheri Kurla Road, Marol Naka, Andheri East, Gamdevi, Marol, Andheri East, Mumbai, Maharashtra 400059

Expires on or after
September, 2027

liver
When it comes to liver issues, caution is advised when using Vogloyd 3D 2.2 Tablet SR. Patients with liver disease should be careful, as dose adjustment may be necessary. It is recommended to consult your doctor before starting this medication. Typically, Vogloyd 3D 2.2 Tablet SR is initiated with a low dose in individuals with mild to moderate liver disease. However, it is not recommended for those with severe liver disease. Always seek medical advice before using this medication if you have liver concerns.

kidney
Vogloyd 3D 2.2 Tablet SR may not be safe for use in patients with kidney issues. It is advised to avoid this medication and consult your doctor. Use in patients with severe kidney disease is not recommended.

alcohol
It is unsafe to drink alcohol while taking Vogloyd 3D 2.2 Tablet SR.

driving
Driving while taking Vogloyd 3D 2.2 Tablet SR can be risky if you experience low or high blood sugar symptoms. Avoid driving in such cases to ensure safety.

pregnancy
Vogloyd 3D 2.2 Tablet SR is considered unsafe during pregnancy due to potential harmful effects on the developing baby, as indicated by animal studies. Your doctor will assess the benefits and risks before prescribing this medication. Please consult your doctor before use.

breastfeeding
Vogloyd 3D 2.2 Tablet SR may not be safe during breastfeeding as it can pass into breastmilk and harm the baby. It is better to consult your doctor before using Vogloyd 3D 2.2 Tablet SR.
| Habit Forming | No |
| Chemical Class | - |
| Therapeutic Class | ANTI DIABETIC |
| Action Class | - |
₹203.34
₹239.22
15% OFF
Inclusive of all taxes
Content verified by

Dr. Upasana Bhatia
MBBS - General Medicine
Last update on 01-Oct-2024


